Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Teva Pharmaceutical Industries ADR (TEVA)

Teva Pharmaceutical Industries ADR (TEVA)
13.26 x 200 13.39 x 200
Post-market by (Cboe BZX)
13.31 -0.34 (-2.49%) 04/21/25 [NYSE]
13.26 x 200 13.39 x 200
Post-market 13.39 +0.08 (+0.60%) 19:07 ET
Quote Overview for Mon, Apr 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
13.04
Day High
13.46
Open 13.46
Previous Close 13.65 13.65
Volume 12,058,900 12,058,900
Avg Vol 12,146,590 12,146,590
Stochastic %K 34.85% 34.85%
Weighted Alpha -28.16 -28.16
5-Day Change -0.15 (-1.11%) -0.15 (-1.11%)
52-Week Range 12.47 - 22.80 12.47 - 22.80
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,476,901
  • Shares Outstanding, K 1,133,839
  • Annual Sales, $ 16,544 M
  • Annual Income, $ -1,639 M
  • EBIT $ 1,228 M
  • EBITDA $ 2,287 M
  • 60-Month Beta 0.72
  • Price/Sales 0.92
  • Price/Cash Flow 3.99
  • Price/Book 2.83

Options Overview Details

View History
  • Implied Volatility 70.27% ( +11.73%)
  • Historical Volatility 54.90%
  • IV Percentile 99%
  • IV Rank 91.28%
  • IV High 74.40% on 04/10/25
  • IV Low 27.03% on 06/11/24
  • Put/Call Vol Ratio 0.13
  • Today's Volume 26,381
  • Volume Avg (30-Day) 27,421
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 796,565
  • Open Int (30-Day) 785,385

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.47
  • Number of Estimates 4
  • High Estimate 0.48
  • Low Estimate 0.45
  • Prior Year 0.46
  • Growth Rate Est. (year over year) +2.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.47 +6.78%
on 04/10/25
Period Open: 16.10
16.28 -18.24%
on 03/24/25
-2.79 (-17.33%)
since 03/21/25
3-Month
12.47 +6.78%
on 04/10/25
Period Open: 21.82
22.40 -40.58%
on 01/28/25
-8.51 (-39.00%)
since 01/21/25
52-Week
12.47 +6.78%
on 04/10/25
Period Open: 12.86
22.80 -41.62%
on 12/27/24
+0.45 (+3.50%)
since 04/19/24

Most Recent Stories

More News
Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings?

AstraZeneca AZN will report its first-quarter 2025 earnings on April 29, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.68 billion and $1.10 per share, respectively....

AZN : 66.90 (-1.02%)
TEVA : 13.31 (-2.49%)
AMGN : 273.68 (-1.30%)
SNY : 50.93 (+0.06%)
Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now

Short-term uncertainty has led to a golden opportunity for long-term investors.

COMP : 6.86 (-5.90%)
$NASX : 15,870.90 (-2.55%)
VZ : 42.93 (-2.52%)
MA : 509.32 (-1.55%)
$SPX : 5,158.20 (-2.36%)
$DOWI : 38,170.41 (-2.48%)
TEVA : 13.31 (-2.49%)
Here's How You Should Play JNJ Stock After Q1 Earnings Beat

Earlier this week, J&J JNJ began the first-quarter earnings season for the drug and biotech sector with better-than-expected results.J&J’s first-quarter adjusted earnings were $2.77 per share, which...

JNJ : 156.92 (-0.35%)
KVUE : 22.27 (-4.79%)
TEVA : 13.31 (-2.49%)
AMGN : 273.68 (-1.30%)
Zacks Industry Outlook Dr. Reddy's, Sandoz and Teva Pharmaceuticals

For Immediate ReleaseChicago, IL – April 16, 2025 – Today, Zacks Equity Research Equity are Dr. Reddy’s Laboratories RDY, Sandoz SDZNY and Teva Pharmaceuticals TEVA.Industry: Generic DrugsLink: https://www.zacks.com/commentary/2448907/3-generic-drug-stocks-to-watch-amid-trade-war-jitters-inflation-woesWhile...

SDZNY : 40.2300 (-0.02%)
RDY : 13.67 (unch)
TEVA : 13.31 (-2.49%)
JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal

Johnson & Johnson’s JNJ first-quarter 2025 earnings came in at $2.77 per share, which beat the Zacks Consensus Estimate of $2.57. Earnings rose 2.2% from the year-ago period.Adjusted earnings exclude...

JNJ : 156.92 (-0.35%)
KVUE : 22.27 (-4.79%)
TEVA : 13.31 (-2.49%)
AMGN : 273.68 (-1.30%)
3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes

While 2025 began on a positive note for the pharmaceutical industry, things have taken a sharp turn amid escalating fears of a global trade war. While Trump had initially exempted pharmaceuticals from...

SDZNY : 40.2300 (-0.02%)
RDY : 13.67 (unch)
TEVA : 13.31 (-2.49%)
5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility

Some of Wall Street's most-prominent asset managers were scooping up shares of time-tested businesses before the stock market meltdown.

COMP : 6.86 (-5.90%)
$NASX : 15,870.90 (-2.55%)
$SPX : 5,158.20 (-2.36%)
AMT : 217.99 (-2.10%)
$DOWI : 38,170.41 (-2.48%)
TEVA : 13.31 (-2.49%)
SIRI : 20.16 (-0.79%)
PM : 162.18 (-0.63%)
ELV : 406.69 (-4.20%)
These Are My 3 Worst-Performing Stocks So Far in 2025 -- and the One I'm Buying More of Now

It's hard to believe, but the first quarter of 2025 is rapidly coming to a close. After doing a quick portfolio checkup, I found that I have stocks that have gained as much as 40% already this year, but...

KIND : 1.4300 (-4.67%)
XYZ : 52.39 (-2.80%)
TEVA : 13.31 (-2.49%)
PINS : 24.21 (-4.16%)
TOST : 33.08 (-3.53%)
Billionaire Stanley Druckenmiller Jettisoned Shares of Palantir and Nvidia, and Is Piling Into 3 High-Profile Turnaround Stocks

Duquesne Family Office's chief is dumping shares of Wall Street's hottest artificial intelligence (AI) stocks in favor of a trio of companies that are righting their respective ships.

NVDA : 96.91 (-4.51%)
BRK.A : 760,489.00 (-2.36%)
BRK.B : 506.92 (-2.18%)
WBD : 7.94 (-2.10%)
TEVA : 13.31 (-2.49%)
PM : 162.18 (-0.63%)
PLTR : 90.80 (-3.18%)
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings

Stanley Druckenmiller, whose net worth is around $6.9 billion, made most of his fortune as a hedge fund manager, and became a well-known name on Wall Street while working for George Soros until 2000.

NTRA : 142.23 (-3.95%)
WWD : 165.22 (-2.33%)
COHR : 52.12 (-5.73%)
CPNG : 21.13 (-1.22%)
TEVA : 13.31 (-2.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets,...

See More

Key Turning Points

3rd Resistance Point 13.92
2nd Resistance Point 13.69
1st Resistance Point 13.50
Last Price 13.31
1st Support Level 13.08
2nd Support Level 12.85
3rd Support Level 12.66

See More

52-Week High 22.80
Fibonacci 61.8% 18.85
Fibonacci 50% 17.63
Fibonacci 38.2% 16.41
Last Price 13.31
52-Week Low 12.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro